<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385760</url>
  </required_header>
  <id_info>
    <org_study_id>CTX-4430-AV-201</org_study_id>
    <nct_id>NCT02385760</nct_id>
  </id_info>
  <brief_title>CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris</brief_title>
  <official_title>A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celtaxsys, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Network Services (CNS) Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celtaxsys Aus Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celtaxsys, Inc.</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and
      safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy as measured by inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in inflammatory lesion count after 12 weeks of treatment as compared to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the incidence of treatment emergent adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of treatment emergent adverse events as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by Investigator Global Assessment (IGA)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of participants achieving Grade 0 or 1 with a two grade improvement in the IGA from baseline to the end of the 12 weeks of treatment as compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by non-inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in non-inflammatory lesion counts after 12 weeks of treatment as compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-4430</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must provide Informed consent.

          2. Male or female aged 18 to 44 inclusive.

          3. Moderate to severe facial acne vulgaris as defined in the protocol.

        Exclusion Criteria:

          1. Positive testing for HIV, HBsAg, or hepatitis C virus (HCV).

          2. Females who are pregnant, lactating, or planning to become pregnant during the study.

          3. Any systemic medical condition which, in the opinion of the investigator, would put
             the participant at risk by participation in the study.

          4. Any systemic or dermatologic disorder that, in the opinion of the investigator will
             interfere with the assessment of the study endpoints (e.g. psoriasis).

          5. Concurrent or previous use of an investigational drug or device within 30 days prior
             to screening.

          6. The presence of acne conglobata, acne fulminans, secondary acne, or nodulocystic
             acne.

          7. The presence of known or suspicious unresolved dermatological cancerous or
             pre-cancerous lesions.

          8. Hypersensitivity or idiosyncratic reaction to compounds related to CTX-4430 or any of
             its components.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynda J Spelman, MB BS, FACD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veracity Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynda Bluck, DPhil BSc</last_name>
    <phone>+64 (0) 21 2299 845</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials Woden Dermatology</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mhairi Craig</last_name>
      <phone>+61 (02) 6282 8410</phone>
      <email>trials@wodendermatology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SouthDerm Southern Suburbs Dermatology</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Levi</last_name>
      <phone>+61 (02) 9553 9118</phone>
      <email>beclevi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Dermatology</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharyn Hutchinson</last_name>
      <phone>+61 (02) 9587 4277</phone>
      <email>clinicaltrials@stgeorgedermatology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Sydney Dermatology</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Hinton</last_name>
      <phone>+61 (02) 9221 1447</phone>
      <email>shintoncoordinator@csdermatology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Nicholls</last_name>
      <phone>+61 (07) 5597 7170</phone>
      <email>carolyn@skincentre.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siller Medical</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory Siller, MBBS FACD</last_name>
      <phone>+61 (07) 3831 4382</phone>
      <email>sillermedical@bigpond.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Davidson</last_name>
      <phone>+61 (07) 3039 1346</phone>
      <email>kurt.davidson@uqconnect.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Veljanoski</last_name>
      <phone>+61 (03) 9623 9400</phone>
      <email>cveljanoski@skincancer.asn.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Pensini</last_name>
      <phone>+61 (08) 9430 4488</phone>
      <email>Ron@fremantledermatology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland Dermatology</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Devonshire</last_name>
      <phone>+64 (9) 631 0088</phone>
      <email>susan.devonshire@dermatology.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials New Zealand</name>
      <address>
        <city>Hamilton</city>
        <zip>3210</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Logan</last_name>
      <phone>+64 (7) 843 0105</phone>
      <email>heather@clinicaltrialsnz.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>March 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Facial Acne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
